RTP Mobile Logo
Beyond the Guidelines: Investigator Perspectives on Current Cases, Clinical Issues and Ongoing Research in the Management of Multiple Myeloma
Released March 2017

Proceedings from Part 2 of a 2-part satellite symposia series during the 58th ASH Annual Meeting. Featuring perspectives from Drs Morie A Gertz, Ola Landgren, Sagar Lonial, María-Victoria Mateos and Robert Z Orlowski. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma (MM).

    Hematologic cancers include the lymphomas, the leukemias, multiple myeloma and other related disorders (eg, myelodysplastic syndrome, myeloproliferative diseases) stemming from lymphoid and myeloid progenitor cell lines. Importantly, currently nearly 70 drug products are labeled for use in the management of hematologic cancers with more than 120 distinct FDA-approved indications. Although this extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors. This is particularly true within the realm of MM, where the past several years have yielded a number of important clinical and research advances.

    Consensus-based guidelines aim to support oncologists and other cancer clinicians in making rational treatment recommendations, but in situations in which multiple “acceptable” therapeutic options exist, such guidelines may not be particularly helpful at the time of decision-making. Because these resources simply enumerate all diagnostic or treatment strategies supported by diverse levels of evidence rather than providing perspectives on the benefits and risks of one strategy versus another, they often leave the clinician alone to contemplate the optimal clinical approach. These proceedings from a CME symposium during the ASH Annual Meeting use an innovative strategy to formally document and present the perspectives, experiences and preferred treatment approaches of 30 myeloma-specific investigators. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of MM with the formulation of up-to-date clinical management strategies.


    • Develop a risk-adapted treatment plan for patients with smoldering MM, considering the roles of observation and active treatment.
    • Use patient- and disease-related factors, including cytogenetic profile, to customize the use of induction and maintenance therapeutic approaches in the transplant and nontransplant settings.
    • Consider available research data and other clinical factors in the best-practice selection, sequencing and combining of current and recently approved novel agents in the nonresearch care of patients with relapsed/refractory MM.
    • Design and implement a plan of care to recognize and manage side effects and toxicities associated with recently approved systemic therapies in order to support quality of life and continuation of treatment.
    • Develop an evidence-based algorithm for the use of stem cell transplant, chemotherapy and/or novel targeted agents in the management of primary amyloidosis.
    • Recall new data with recently approved and investigational agents demonstrating promising activity in Waldenström macroglobulinemia, and, as applicable, integrate these strategies into the protocol and nonresearch care of patients.
    • Identify ongoing trials of investigational approaches in MM, amyloidosis and Waldenström macroglobulinemia, and refer appropriate patients and obtain consent for study participation.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Research To Practice designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity enables the participant to earn up to 2.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASHMM17/CME.

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Morie A Gertz, MD, MACP
    Division of Hematology
    Roland Seidler Jr Professor and Chair
    Department of Medicine
    College of Medicine
    Mayo Distinguished Clinician
    Mayo Clinic
    Rochester, Minnesota

    Consulting Agreements: Amgen Inc, GlaxoSmithKline, Novartis Pharmaceuticals Corporation.

    Ola Landgren, MD, PhD
    Professor of Medicine
    Weill Cornell Medical College
    Chief, Myeloma Service
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Merck, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Oncology.

    Sagar Lonial, MD
    Professor and Executive Vice Chair
    Department of Hematology and Medical Oncology
    Chief Medical Officer
    Winship Cancer Institute
    Emory University
    Atlanta, Georgia

    Advisory Committee and Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Oncology.

    María-Victoria Mateos, MD, PhD
    Physician in Hematology
    University Hospital of Salamanca
    Salamanca, Spain

    Advisory Committee: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Takeda Oncology.

    Robert Z Orlowski, MD, PhD
    Florence Maude Thomas Cancer Research Professor
    Chair ad interim, Department of Lymphoma and Myeloma
    Professor, Department of Experimental Therapeutics
    Division of Cancer Medicine
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, FORMA Therapeutics, Janssen Biotech Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Oncology; Contracted Research: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Spectrum Pharmaceuticals Inc, Takeda Oncology.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Agendia Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.  

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP/Acerta Pharma, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech BioOncology, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Merck, Pharmacyclics LLC, an AbbVie Company, Seattle Genetics and Takeda Oncology.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: March 2017
    Expiration date: March 2018

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):

Dr Love: Introduction

Dr Landgren — Introduction

  • Up-Front Management of Newly Diagnosed Multiple Myeloma

Dr Landgren — Presentation

  • Up-Front Management of
    Newly Diagnosed Multiple Myeloma

Dr Mateos — Introduction

  • Consolidation and Maintenance Therapy

Dr Mateos — Presentation

  • Consolidation and Maintenance Therapy

Dr Lonial — Introduction

  • Management of Relapsed/Refractory Disease, Part I

Dr Lonial — Presentation

  • Management of Relapsed/Refractory Disease, Part I

Dr Gertz — Introduction

  • Management of Relapsed/Refractory Disease, Part II

Dr Gertz — Presentation

  • Management of Relapsed/Refractory Disease, Part II

Dr Orlowski — Introduction

  • Smoldering Myeloma, Waldenström Macroglobulinemia and Primary Amyloidosis

Dr Orlowski — Presentation

  • Smoldering Myeloma, Waldenström Macroglobulinemia and Primary Amyloidosis